## Michael A Liss

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/946646/publications.pdf Version: 2024-02-01



MICHAELALISS

#	Article	IF	CITATIONS
1	An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. Journal of Urology, 2017, 198, 329-334.	0.2	151
2	Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. European Urology, 2018, 74, 575-582.	0.9	117
3	Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. European Urology, 2016, 69, 407-410.	0.9	51
4	Systematic review of modifiable risk factors for kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 359-371.	0.8	37
5	The Microbiome and Prostate Cancer Risk. Current Urology Reports, 2019, 20, 66.	1.0	33
6	A case control study of sarcosine as an early prostate cancer detection biomarker. BMC Urology, 2015, 15, 99.	0.6	28
7	Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study. Prostate Cancer and Prostatic Diseases, 2019, 22, 244-251.	2.0	27
8	Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer. Cancer Research, 2021, 81, 4110-4123.	0.4	25
9	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. European Urology Focus, 2019, 5, 54-61.	1.6	18
10	Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 340.e1-340.e6.	0.8	16
11	Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus. Advances in Urology, 2020, 2020, 1-6.	0.6	15
12	Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 531-538.	2.0	15
13	Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer. Cancers, 2019, 11, 1910.	1.7	14
14	Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGFÎ <sup>2</sup> signaling. Communications Biology, 2020, 3, 12.	2.0	14
15	Comparison of rectal swab, glove tip, and participant-collected stool techniques for gut microbiome sampling. BMC Microbiology, 2021, 21, 26.	1.3	14
16	Inflammation appears as high Prostate Imaging–Reporting and Data System scores on prostate magnetic resonance imaging (MRI) leading to false positive MRI fusion biopsy. Investigative and Clinical Urology, 2019, 60, 388.	1.0	14
17	GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. Molecular Cancer Research, 2022, 20, 62-76.	1.5	14
18	lmmunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology, 2019, 124, 168-173.	0.5	12

MICHAEL A LISS

#	Article	lF	CITATIONS
19	Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2454-2462.	1.1	12
20	Novel Use of Household Items in Open and Robotic Surgical Skills Resident Education. Advances in Urology, 2019, 2019, 1-6.	0.6	10
21	The Application of Regional Hypothermia Using Transrectal Cooling During Radical Prostatectomy: Mitigation of Surgical Inflammatory Damage to Preserve Continence. Journal of Endourology, 2012, 26, 1553-1557.	1.1	6
22	Prospective Implementation of a Point-of-Care PCR-Based Detection Method to Guide Antibiotic Use Prior to Prostate Biopsy Compared to Targeted Prophylaxis and Physician Choice. Urology, 2019, 129, 87-91.	0.5	6
23	Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. Cancer Prevention Research, 2021, 14, 551-562.	0.7	6
24	mTOR inhibitors for treatment of low-risk prostate cancer. Medical Hypotheses, 2018, 117, 63-68.	0.8	5
25	Systematic Review of Current Ultrasound Use in Education and Simulation in the Field of Urology. Current Urology Reports, 2020, 21, 23.	1.0	5
26	Validation of 3D volumetric-based renal function prediction calculator for nephron sparing surgery. International Urology and Nephrology, 2017, 49, 615-621.	0.6	4
27	Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 231-239.	0.8	4
28	Histological variants of non–muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 275.e1-275.e10.	0.8	4
29	Microbiome diversity in carriers of fluoroquinolone resistant <i>Escherichia coli</i> . Investigative and Clinical Urology, 2019, 60, 75.	1.0	3
30	Feasibility of dietary folic acid reduction intervention for men on active surveillance for prostate cancer. Clinical Nutrition ESPEN, 2021, 44, 270-275.	0.5	3
31	Rise in serum folate after androgen deprivation associated with worse prostate cancer-specific survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 682.e21-682.e27.	0.8	3
32	Initial Evaluation of Computer-Assisted Radiologic Assessment for Renal Mass Edge Detection as an Indication of Tumor Roughness to Predict Renal Cancer Subtypes. Advances in Urology, 2019, 2019, 1-8.	0.6	2
33	Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer. Clinical Genitourinary Cancer, 2022, 20, 237-243.	0.9	2
34	Novel Definitions of Low-risk and High-risk Prostate Cancer: Implications for the European Randomized Study of Screening for Prostate Cancer Risk Assessment Tool. European Urology, 2017, 72, 52-53.	0.9	1
35	A randomized controlled trial of a home-based exercise program on prognostic biomarkers in men with prostate cancer: A study protocol. Contemporary Clinical Trials Communications, 2020, 20, 100659.	0.5	1
36	Transitional Care of Service Members With Genitourinary Injury. Military Medicine, 2021, 186, 969-974.	0.4	0

#	Article	IF	CITATIONS
37	Prevalence of pathogenic germline cancer risk variants in testicular cancer patients: Identifying high risk groups. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0